Bavarian Nordic Announces Interim Results for the First Nine Months of 2022

On November 9, 2022 Bavarian Nordic A/S (OMX: BAVA) reported its interim financial results for the first nine months of 2022 and business progress for the third quarter of 2022 (Press release, Bavarian Nordic, NOV 9, 2022, View Source [SID1234623755]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Paul Chaplin, President & Chief Executive Officer of Bavarian Nordic said: "These are exciting times for Bavarian Nordic as we have continued to expand our activities to support the global response against monkeypox, while also running two global Phase 3 trials of our late-stage pipeline assets. We are highly encouraged to see how our vaccines can truly make a difference by providing comfort for the populations at-risk and helping to change the course of the monkeypox outbreak. More than 1 million people have received our vaccine since the beginning of the outbreak and the number grows day by day and we have already secured significant orders for 2023 and beyond. Deliveries were intensified over the last 3 months and will continue into the fourth quarter as we expand the supply of our smallpox/monkeypox vaccine to more than 70 countries worldwide. The increased sales of our products across the portfolio are driving all-time high revenues and we are nearing an EBITDA break-even result for 2022."

Financial highlights

Total revenue in the first nine months was DKK 1,860 million comprised of DKK 1,752 million from product sales, DKK 83 million in milestone payments from partners and DKK 25 million from contract work.
Revenue in the third quarter totaled DKK 1,004 million comprised of DKK 338 million from sale of Rabipur/RabAvert, DKK 62 million from sale of Encepur, DKK 578 million from sale of JYNNEOS/IMVANEX/IMVAMUNE, DKK 11 million from sale of third-party products and DKK 15 million from contract work.
EBITDA for the first nine months was DKK 14 million.
Cash position of DKK 2,741 million at the end of third quarter.
The most recent financial guidance for the full year, issued on September 7, is maintained at revenues between DKK 2,800 and 3,000 million, EBITDA with a loss between DKK -200 and 0 million and cash and cash equivalents at year-end expected to exceed DKK 1,700 million.

Other highlights

Monkeypox

In July, the U.S. government ordered an additional 5 million doses of monkeypox vaccine for delivery in 2022 and 2023. The vaccines will be filled using existing bulk vaccine, manufactured and invoiced under previous contracts with the U.S. government. To expand the manufacturing footprint to increase supply, the doses will also be filled at a U.S. based contract manufacturer following the tech transfer of the manufacturing process.
In July, the European Commission approved an extension of the current marketing authorization for the Company’s smallpox vaccine, IMVANEX to include protection from monkeypox and disease caused by vaccinia virus.
In July, Bavarian Nordic received approvals from the U.S. and EU regulatory authorities of the fill and finish manufacturing of smallpox and monkeypox vaccine at the Company’s new facility in Denmark.
In August, Bavarian Nordic entered a supply agreement with the Pan American Health Organization (PAHO) enabling access to monkeypox vaccines for countries in Latin America.
In September, Bavarian Nordic was awarded a ten-year contract valued up to USD 434 million for the supply of smallpox and monkeypox vaccine to Canada.
In September, Bavarian Nordic entered an additional contract with the European Health Emergency Preparedness and Response Authority (HERA) for the supply of monkeypox vaccines to EU Member States.
Additional orders for monkeypox vaccine were entered during the quarter with several governments, including significant orders for 2023, bringing the total number of countries with access to the vaccine to over 70.
RSV

Enrollment is proceeding as planned in the global Phase 3 clinical trial of MVA-BN RSV against RSV in older adults.
ABNCoV2 (COVID-19)

In September, Bavarian Nordic initiated a global Phase 3 clinical trial of its COVID-19 booster vaccine candidate, ABNCoV2. The trial will assess the non-inferiority of ABNCoV2 compared to Comirnaty in terms of neutralizing antibodies against the SARS-CoV-2 (Wuhan wild type).
Other business

In September, the board of directors appointed Luc Debruyne, former President Global Vaccines at GSK, as an observer to the board with the intent to nominate him for election to the board at the ordinary general meeting in March 2023, where he, following the board’s constitution, is expected to assume the chairmanship after Gerard van Odijk, who will step down after having served for 15 years on the board.
Events after the reporting date

In October, Bavarian Nordic signed its first bilateral agreement with a country in Latin America on the supply of monkeypox vaccines, thus expanding access to the vaccine in the region beyond the availability of vaccines through PAHO.
In October, the Company furthermore entered a supply agreement for monkeypox vaccines to Switzerland. Under this agreement, Bavarian Nordic will seek regulatory approval of the vaccine with Swissmedic.
In October, Bavarian Nordic reported results from a six-month follow-up analysis of data from subjects vaccinated in the Phase 2 clinical trial of its COVID-19 booster vaccine candidate, ABNCoV2, demonstrating that six months post the booster vaccination with ABNCoV2, the neutralization antibody titers against Wuhan and the Omicron variant remained high and at levels associated with a greater than 90% efficacy.
Conference call and webcast
The management of Bavarian Nordic will host an investor/analyst call today at 2 pm CET (8 am EST) to present the interim results followed by a Q&A session. A listen-only version of the call and presentation slides can be accessed via https://bit.ly/3Mud65F. To join the Q&A session, please register in advance via https://bit.ly/3g5j4gR.

Entry into a Material Definitive Agreement

On November 9, 2022 Arrowhead Pharmaceuticals, Inc. (the "Company") reported that entered into a Royalty Purchase Agreement (the "Purchase Agreement") with Royalty Pharma Investments 2019 ICAV ("Royalty Pharma"), pursuant to which Royalty Pharma agreed to pay up to $410 million in cash to the Company in consideration for the Company’s future royalty interest in Olpasiran, a small interfering RNA (siRNA) originally developed by the Company and licensed to Amgen in 2016 under that certain Second Collaboration and License Agreement (the "License Agreement") (Filing, 8-K, Arrowhead Research Corporation, NOV 9, 2022, View Source [SID1234623701]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Pursuant to the Purchase Agreement, Royalty Pharma paid $250 million upfront and agreed to pay up to an additional $160 million in aggregate one-time milestone payments due if and when the following milestone events occur: (i) $50 million on completion of enrollment in the planned OCEAN Phase 3 clinical trial for Olpasiran, (ii) $50 million upon receipt of FDA approval of Olpasiran for an approved indication (reduction in the risk of myocardial infarction, urgent coronary revascularization, or coronary heart disease death in adults with established cardiovascular disease and elevated Lp(a)), and (iii) $60 million upon Royalty Pharma’s receipt of at least $70 million of royalty payments under the Purchase Agreement in any single calendar year.

In consideration for the payment of the foregoing amounts under the Purchase Agreement, Royalty Pharma is entitled to receive all royalties otherwise payable by Amgen to the Company under the License Agreement. The Company remains eligible to receive any milestone payments potentially payable by Amgen under the License Agreement.

The Purchase Agreement contains other customary terms and conditions, including representations and warranties, covenants, and indemnification obligations in favor of each party. The above description of the Purchase Agreement is a summary of the material terms, does not purport to be complete and is qualified in its entirety by reference to the Purchase Agreement, which will be filed as an exhibit to the Company’s Quarterly Report on Form 10-Q for the quarter ending December 31, 2022.

Concert Pharmaceuticals to Participate in Fireside Chat at the Jefferies London Healthcare Conference

On November 9, 2022 Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) reported that it will participate in a fireside chat at the Jefferies London Healthcare Conference on November 16, 2022, at 10:20 a.m. GMT (Press release, Concert Pharmaceuticals, NOV 9, 2022, View Source [SID1234623655]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A webcast of the presentation may be accessed in the Investors section of the Company’s website at www.concertpharma.com. A replay will be available on Concert’s website for two weeks following the presentation.

Decibel Therapeutics Reports Third Quarter 2022 Financial Results and Corporate Update

On November 9, 2022 Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, reported financial results for the third quarter ended September 30, 2022 and provided a corporate update (Press release, Decibel Therapeutics, NOV 9, 2022, View Source [SID1234623654]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Decibel continued to maintain strong momentum throughout 2022 as we achieved the goals we set forth for the year. The FDA clearance of our IND application and the submission of our CTAs in the UK and Spain for our lead gene therapy product candidate, DB-OTO, mark significant milestones for us, and we look forward to initiating the Phase 1/2 clinical trial in the first half of 2023," said Laurence Reid, Ph.D., Chief Executive Officer of Decibel. "Looking ahead, we plan to continue to strengthen our position as a leader in the broader hearing loss space and we look forward to the opportunity to further our goal of developing transformative gene therapies for the inner ear."

Pipeline Highlights and Upcoming Milestones:

Gene Therapies for Congenital, Monogenic Hearing Loss

Received FDA Clearance of IND Application for DB-OTO: In October 2022, Decibel announced that it had received clearance from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application to initiate a Phase 1/2 clinical trial in pediatric patients of DB-OTO, its lead gene therapy product candidate. DB-OTO is being developed in collaboration with Regeneron Pharmaceuticals and is an adeno-associated virus (AAV)-based dual-vector gene therapy designed to provide durable hearing to individuals with profound congenital hearing loss caused by mutations of the otoferlin gene. DB-OTO uses a proprietary, cell-selective promoter to express the otoferlin transgene in hair cells, with the goal of enabling the ear to transmit sound to the brain and provide hearing to such individuals. DB-OTO received Orphan Drug and Rare Pediatric Disease designations from the FDA in 2021.
CTA Applications Filed for DB-OTO in Europe: In November 2022, Decibel announced submission of Clinical Trial Applications (CTAs) to the Medicines and Healthcare Products Regulatory Agency (MHRA) in the United Kingdom and the Spanish Agency of Medicines and Medical Devices (AEMPS) for a Phase 1/2 clinical trial of DB-OTO in pediatric patients.
Plan to Identify a Product Candidate for AAV.103 Program in Fourth Quarter of 2022: Decibel plans to select a product candidate for further development in its AAV.103 program to restore hearing in individuals with mutations in the gap junction beta-2 (GJB2) gene, the most common cause of autosomal recessive, non-syndromic, congenital hearing loss. Decibel is developing the AAV.103 program in collaboration with Regeneron Pharmaceuticals and retains global commercial rights to the AAV.103 program.
Otoprotection Therapeutic

Intend to Provide Update on DB-020 in First Half of 2023: Decibel plans to report additional data from the interim analysis of the Phase 1b clinical trial of DB-020 at an upcoming conference. The Company continues to evaluate strategic opportunities to continue development of DB-020, including seeking feedback from regulatory authorities.
Corporate Update:

Board of Directors Update: In October 2022, Decibel announced the appointment of Kevin F. McLaughlin to its Board of Directors. Kevin brings more than 40 years of financial and operating management experience spanning the biotech, high-tech and education industries.
Third Quarter 2022 Financial Results:

Cash Position: As of September 30, 2022, cash, cash equivalents and available-for-sale securities were $111.9 million, compared to $162.3 million as of December 31, 2021.
Research and Development Expenses: Research and development expenses were $10.0 million for the third quarter of 2022, compared to $9.0 million for the same period in 2021. The increase in research and development expenses for the third quarter of 2022 was primarily due to additional costs to advance DB-OTO in support of the Company’s IND filing, higher research costs related to preclinical gene therapy programs and higher personnel-related costs due to increased headcount, wages and stock-based compensation.
General and Administrative Expenses: General and administrative expenses were $6.3 million for the third quarter of 2022, compared to $5.7 million for the same period in 2021. The increase in general and administrative expenses for the third quarter of 2022 was primarily due to higher professional fees including external consulting, advisory, legal and audit services.
Financial Guidance:

Based on its current operating and development plans, Decibel believes that its existing cash, cash equivalents and available-for-sale securities will fund its operating expenses into 2024.

Revolution Medicines to Participate in Upcoming Investor Conferences

On November 9, 2022 Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, reported that the company will participate in two upcoming investor conferences (Press release, Revolution Medicines, NOV 9, 2022, View Source [SID1234623652]). Mark A. Goldsmith, M.D., Ph.D., chief executive officer and chairman of Revolution Medicines, will be the featured speaker in fireside chats at the H.C. Wainwright 3rd Annual Precision Oncology Virtual Conference and the 5th Annual Evercore ISI HealthCONx Conference .

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details of these events are as follows:

H.C. Wainwright 3rd Annual Precision Oncology Virtual Conference
Conference Date: November 14, 2022
Fireside Chat Time/Date: 7:00 a.m. Eastern on Monday, November 14, 2022
Format: Virtual conference; webcast available
5th Annual Evercore ISI HealthCONx Conference
Conference Date: November 29 – December 1, 2022
Fireside Chat Time/Date: 2:15 p.m. Eastern on Thursday, December 1, 2022
Format: Virtual conference; webcast available
Webcasts of the H.C. Wainwright and Evercore ISI fireside chats can be accessed at: View Source Archived replays of the webcasts will be available on the investors section of the company’s website for at least 14 days following the events.